# Richard Haycock

> Richard Haycock is a seed investor at QantX (Kingswear) backing Health Care and Medical. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [QantX](https://shizune.co/investors/profile/qantx)
- Location: Kingswear, United Kingdom
- Total investments: 9
- Last investment: Jul 2026
- Lead investor: 22%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/rhaycock/

Richard Haycock is a seed investor at QantX in Kingswear focused on Health Care and Medical. Richard Haycock is the Co-Founder & CEO QantX.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 33% |
| Medical | 2 | 22% |
| Biotechnology | 2 | 22% |
| Pharmaceutical | 2 | 22% |
| Oncology | 1 | 11% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 33% |
| Pre-Seed | 2 | 22% |
| Funding Round | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Revolver Therapeutics | Revolver Therapeutics develops peptide therapeutics that target transcription factors to create new routes to cancer treatment. The company uses a proprietary peptide discovery and screening platform, including its Transcription Block Survival technology, to identify functional peptide inhibitors in live cell systems. This platform enables rapidscreening of large peptide libraries and enrichment of molecules that functionally block or modulate transcription factor activity. Revolver Therapeutics focuses on translating its peptide-based transcription factor screening technology into therapeutic candidates for oncology. Its work is based on research spun out from the University of Bath and is aimed at generating next-generation peptide drugs for difficult-to-treat cancers. | $764K | Pre-Seed | Jul 03, 2026 |  |
| iFast Diagnostics | iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $3.9M | Seed | May 27, 2026 |  |
| EnsiliTech | EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M | Seed | Aug 28, 2025 |  |
| iFast Diagnostics | iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $6.5M | Seed | Nov 04, 2024 |  |
| Senisca | Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.8M |  | Mar 18, 2024 |  |
| Senisca | Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.7M | Seed | Mar 18, 2024 |  |
| iFast Diagnostics | iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $2.4M | Seed | Feb 16, 2023 |  |
| EnsiliTech | EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $1.1M | Pre-Seed | Jan 17, 2023 |  |
| Senisca | Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $2.5M | Seed | Jun 09, 2022 |  |

9 of 9 investments shown.

## Co-investors
- [APEX Ventures](https://shizune.co/investors/profile/apex-ventures-2) — VC Fund, 4 deals together
- [Meridian Health Ventures](https://shizune.co/investors/profile/khp-ventures) — VC Fund, 4 deals together
- [Emerging Longevity Ventures](https://shizune.co/investors/profile/emerging-longevity-ventures) — VC Fund, 3 deals together
- [Empirical Ventures](https://shizune.co/investors/profile/empirical-ventures) — VC Fund, 3 deals together
- [Lifespan Vision Ventures](https://shizune.co/investors/profile/lifespan-vision-ventures) — VC Fund, 3 deals together
- [R42 Group](https://shizune.co/investors/profile/r42-group) — VC Fund, 3 deals together

## About QantX

VC Fund · Exeter, United Kingdom

High impact innovation investment

1 contacts available at QantX.

| Name | Title | Profile |
| --- | --- | --- |
| Richard Haycock | CEO | https://shizune.co/investors/profile/richard-haycock-6928 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Richard Haycock invest in?

Richard Haycock invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Richard Haycock last invest?

The most recent investment recorded for Richard Haycock closed in Jul 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co